Ehsan Ghorani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ehsan Ghorani has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Ananya Saha
Emory University 2 Department of Biology Atlanta, GA
9 shared publications - Annapaola Mariniello
University of Geneva 16 Department of Pathology and Immunology Geneva
9 shared publications - Daniel T. McManus
Emory Vaccine Center, Emory University School of Medicine, Atlanta, USA
9 shared publications - Daniel Y. Chang
Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA
9 shared publications - Dario Sangiolo
Dipartimento di Oncologia, Università di Torino, Regione Gonzole 10, 10043 Orbassano, Italy; Candiolo Cancer Institute, FPO-IRCCS, Viale della Ricerca 7, 10060 Candiolo, Turin, Italy
9 shared publications - Donald J. McGuire
Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA
9 shared publications
Latest Publications
- 5 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF16
FasL-Mediated Death of Activated Intratumoral T Cells Drives Secondary Resistance to Cancer Immunotherapy
Cancer progression following an initial response to immunotherapy [secondary resistance (2°R)] is a major and poorly understood problem. We treated mice bearing B16 melanoma with a combination of a regulatory T cell (Treg)–depleting, non–IL2-blocking anti-CD25 (anti-CD25NIB) antibody and an autologous cancer cell vaccine (GVAX). The regimen yielded initial tumor shrinkage followed by 2°R; lethal progression occurred in ∼90% of partially responsive (PR) tumors by days 35 to 50. Cell lines derived from 2°R tumors retained treatment sensitivity upon reimplantation into naïve mice, suggesting that resistance was related to a loss of immune control over time. Profiling PR and 2°R tumors by flow cytometry and single-cell RNA/T-cell receptor (TCR) sequencing, we found that activated CD8+ T cells with tumor-reactive features declined in abundance, whereas nonactivated T cells and Tregs increased. Activated CD8+ cells showed heightened TCR stimulation, clonal expansion, and expression of apoptotic signatures and death receptors, including Fas. Their loss was not explained by lymph node accumulation or differentiation to nonactivated states. These findings were validated in a clinically relevant MC38 colon carcinoma model treated with anti–PD-L1 checkpoint blockade, confirming that depletion of activated, tumor-reactive clones is a shared mechanism of 2°R across therapeutic modalities. Fas ligand (FasL) blockade reversed this loss and prolonged survival. Longitudinal transcriptional and tissue staining data from human checkpoint blockade studies similarly indicated that activated T cells decline in abundance over time and at 2°R. These findings implicate death of activated T cells as a mechanism of 2°R and suggest that Fas–FasL blockade may extend response durability.
- 5 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF16
FasL-Mediated Death of Activated Intratumoral T Cells Drives Secondary Resistance to Cancer Immunotherapy
Cancer progression following an initial response to immunotherapy [secondary resistance (2°R)] is a major and poorly understood problem. We treated mice bearing B16 melanoma with a combination of a regulatory T cell (Treg)–depleting, non–IL2-blocking anti-CD25 (anti-CD25NIB) antibody and an autologous cancer cell vaccine (GVAX). The regimen yielded initial tumor shrinkage followed by 2°R; lethal progression occurred in ∼90% of partially responsive (PR) tumors by days 35 to 50. Cell lines derived from 2°R tumors retained treatment sensitivity upon reimplantation into naïve mice, suggesting that resistance was related to a loss of immune control over time. Profiling PR and 2°R tumors by flow cytometry and single-cell RNA/T-cell receptor (TCR) sequencing, we found that activated CD8+ T cells with tumor-reactive features declined in abundance, whereas nonactivated T cells and Tregs increased. Activated CD8+ cells showed heightened TCR stimulation, clonal expansion, and expression of apoptotic signatures and death receptors, including Fas. Their loss was not explained by lymph node accumulation or differentiation to nonactivated states. These findings were validated in a clinically relevant MC38 colon carcinoma model treated with anti–PD-L1 checkpoint blockade, confirming that depletion of activated, tumor-reactive clones is a shared mechanism of 2°R across therapeutic modalities. Fas ligand (FasL) blockade reversed this loss and prolonged survival. Longitudinal transcriptional and tissue staining data from human checkpoint blockade studies similarly indicated that activated T cells decline in abundance over time and at 2°R. These findings implicate death of activated T cells as a mechanism of 2°R and suggest that Fas–FasL blockade may extend response durability.
- 20 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (18) , 1720-1729
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond
PURPOSE: Malignant ovarian germ cell tumors (MOGCTs) are rare, aggressive malignancies predominantly affecting young women. Unlike testicular germ cell tumors, prognostic factors are poorly understood, with small studies suggesting advanced stage as an adverse factor. Here, we examine a large international series to identify relevant prognostic factors. METHODS: We analyzed data from 254 patients with International Federation of Gynecology and Obstetrics stage IC-IV MOGCT, requiring surgery and chemotherapy between 1971 and 2018 at two UK and the Multicenter Italian Trials in Ovarian Cancer centers. RESULTS: The median age was 27 years (IQR, 21-31). Initial treatment was surgery in 87.8% of patients (50.4% fertility sparing, 37.4% nonsparing) or neoadjuvant chemotherapy. Most underwent BEP or POMB/ACE chemotherapy, with 32.5% receiving high-dose chemotherapy (HDCT) at relapse. First-line treatment resulted in a complete response in 84.6% (n = 215) and partial response or stable disease in 7.9% (n = 20), while 4.7% (n = 12) progressed. Overall, 37 patients (14.6%) died of disease. Ten-year progression-free survival and cancer-specific survival (CSS) was 82.8% (95% CI, 77.2 to 87.2) and 83.2% (95% CI, 77.3 to 87.7), respectively. CSS for stage IV disease was 79.4% (95% CI, 69.5 to 86.4). Age ≥35 years (hazard ratio [HR], 2.8 [95% CI, 1.5 to 5.4]; P = .003), stage III/IV disease (HR, 1.4 [95% CI, 1,0.2 to 1.9]; P = .035), and nondysgerminoma histology (HR, 7.3 [95% CI, 1.9 to 64.8]; P = .01) had worse CSS on multivariable analysis. By contrast, CSS of immature grade 2/3 MOGCT mirrored dysgerminomas. HDCT appeared to improve survival in first but not later relapses. CONCLUSION: Advanced stage (III/IV), age >35 years, and nondysgerminoma (excluding grade 2/3 immature teratomas) are adverse prognostic factors. Stage IV disease can achieve 80% long-term survival rates, and HDCT improves survival in first but not second relapse.
- 20 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (18) , 1720-1729
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond
PURPOSE: Malignant ovarian germ cell tumors (MOGCTs) are rare, aggressive malignancies predominantly affecting young women. Unlike testicular germ cell tumors, prognostic factors are poorly understood, with small studies suggesting advanced stage as an adverse factor. Here, we examine a large international series to identify relevant prognostic factors. METHODS: We analyzed data from 254 patients with International Federation of Gynecology and Obstetrics stage IC-IV MOGCT, requiring surgery and chemotherapy between 1971 and 2018 at two UK and the Multicenter Italian Trials in Ovarian Cancer centers. RESULTS: The median age was 27 years (IQR, 21-31). Initial treatment was surgery in 87.8% of patients (50.4% fertility sparing, 37.4% nonsparing) or neoadjuvant chemotherapy. Most underwent BEP or POMB/ACE chemotherapy, with 32.5% receiving high-dose chemotherapy (HDCT) at relapse. First-line treatment resulted in a complete response in 84.6% (n = 215) and partial response or stable disease in 7.9% (n = 20), while 4.7% (n = 12) progressed. Overall, 37 patients (14.6%) died of disease. Ten-year progression-free survival and cancer-specific survival (CSS) was 82.8% (95% CI, 77.2 to 87.2) and 83.2% (95% CI, 77.3 to 87.7), respectively. CSS for stage IV disease was 79.4% (95% CI, 69.5 to 86.4). Age ≥35 years (hazard ratio [HR], 2.8 [95% CI, 1.5 to 5.4]; P = .003), stage III/IV disease (HR, 1.4 [95% CI, 1,0.2 to 1.9]; P = .035), and nondysgerminoma histology (HR, 7.3 [95% CI, 1.9 to 64.8]; P = .01) had worse CSS on multivariable analysis. By contrast, CSS of immature grade 2/3 MOGCT mirrored dysgerminomas. HDCT appeared to improve survival in first but not later relapses. CONCLUSION: Advanced stage (III/IV), age >35 years, and nondysgerminoma (excluding grade 2/3 immature teratomas) are adverse prognostic factors. Stage IV disease can achieve 80% long-term survival rates, and HDCT improves survival in first but not second relapse.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A-C) Relative frequency of stem-like (PD-1+TCF-1+TIM-3-) (A), transitory effector (PD-1+CX3CR1+TIM-3+) (B), and terminally differentiated (PD-1+CD101+TIM-3+) (C) Gp276+ and Gp33+ CD8 T cells in the spleen across treatment groups. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis the one-way ANOVA test was used. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A-C) Relative frequency of stem-like (PD-1+TCF-1+TIM-3-) (A), transitory effector (PD-1+CX3CR1+TIM-3+) (B), and terminally differentiated (PD-1+CD101+TIM-3+) (C) Gp276+ and Gp33+ CD8 T cells in the spleen across treatment groups. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis the one-way ANOVA test was used. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A) Design of the acute LCMV infection experiment. (B) Number of total CD8+ T cells, and of activated (CD44high) and naïve (CD44low) CD8+ T cells in the spleen of acutely infected mice after treatment in the two groups. (C) Representative FACS plots showing frequency of Gp33+ and Gp276+ CD8 T cells in the spleen across the two groups, quantified numbers are shown on the right. Data are representative of one out of 2 independent experiments of 3-5 mice per group. For statistical analysis the T-test was used; total numbers were Log10 transformed. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A) Design of the acute LCMV infection experiment. (B) Number of total CD8+ T cells, and of activated (CD44high) and naïve (CD44low) CD8+ T cells in the spleen of acutely infected mice after treatment in the two groups. (C) Representative FACS plots showing frequency of Gp33+ and Gp276+ CD8 T cells in the spleen across the two groups, quantified numbers are shown on the right. Data are representative of one out of 2 independent experiments of 3-5 mice per group. For statistical analysis the T-test was used; total numbers were Log10 transformed. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A-C) Relative frequency of stem-like (PD-1+TCF-1+TIM-3-) (A), transitory effector (PD-1+CX3CR1+TIM-3+) (B), and terminally differentiated (PD-1+CD101+TIM-3+) (C) Gp276+ and Gp33+ CD8 T cells in the spleen across treatment groups. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis the one-way ANOVA test was used. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A-C) Relative frequency of stem-like (PD-1+TCF-1+TIM-3-) (A), transitory effector (PD-1+CX3CR1+TIM-3+) (B), and terminally differentiated (PD-1+CD101+TIM-3+) (C) Gp276+ and Gp33+ CD8 T cells in the spleen across treatment groups. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis the one-way ANOVA test was used. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A) Design of the acute LCMV infection experiment. (B) Number of total CD8+ T cells, and of activated (CD44high) and naïve (CD44low) CD8+ T cells in the spleen of acutely infected mice after treatment in the two groups. (C) Representative FACS plots showing frequency of Gp33+ and Gp276+ CD8 T cells in the spleen across the two groups, quantified numbers are shown on the right. Data are representative of one out of 2 independent experiments of 3-5 mice per group. For statistical analysis the T-test was used; total numbers were Log10 transformed. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A) Design of the acute LCMV infection experiment. (B) Number of total CD8+ T cells, and of activated (CD44high) and naïve (CD44low) CD8+ T cells in the spleen of acutely infected mice after treatment in the two groups. (C) Representative FACS plots showing frequency of Gp33+ and Gp276+ CD8 T cells in the spleen across the two groups, quantified numbers are shown on the right. Data are representative of one out of 2 independent experiments of 3-5 mice per group. For statistical analysis the T-test was used; total numbers were Log10 transformed. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
A) Number of total lymphocytes and of CD8+ T cells in the spleen of mice treated with either concomitant or sequential combination of CT and aPD-L1. (B) Representative FACS plots showing the frequency of stem-like (PD-1+TCF-1+TIM-3-), effector transitory (PD-1+CX3CR1+TIM-3+) and terminally differentiated (PD-1+CD101+TIM-3+) Gp33+ CD8 T cells in the spleen across the treatment groups, with quantified numbers shown in (C). Data are pooled from 2 independent experiments of 4-6 mice per group. For statistical analysis the T-test was used, total numbers were Log10 transformed. Bars represent mean and SEM. * p<0.05; ** p<0.01; **** p<0.0001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
A) Number of total lymphocytes and of CD8+ T cells in the spleen of mice treated with either concomitant or sequential combination of CT and aPD-L1. (B) Representative FACS plots showing the frequency of stem-like (PD-1+TCF-1+TIM-3-), effector transitory (PD-1+CX3CR1+TIM-3+) and terminally differentiated (PD-1+CD101+TIM-3+) Gp33+ CD8 T cells in the spleen across the treatment groups, with quantified numbers shown in (C). Data are pooled from 2 independent experiments of 4-6 mice per group. For statistical analysis the T-test was used, total numbers were Log10 transformed. Bars represent mean and SEM. * p<0.05; ** p<0.01; **** p<0.0001.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
A) Number of total lymphocytes and of CD8+ T cells in the spleen of mice treated with either concomitant or sequential combination of CT and aPD-L1. (B) Representative FACS plots showing the frequency of stem-like (PD-1+TCF-1+TIM-3-), effector transitory (PD-1+CX3CR1+TIM-3+) and terminally differentiated (PD-1+CD101+TIM-3+) Gp33+ CD8 T cells in the spleen across the treatment groups, with quantified numbers shown in (C). Data are pooled from 2 independent experiments of 4-6 mice per group. For statistical analysis the T-test was used, total numbers were Log10 transformed. Bars represent mean and SEM. * p<0.05; ** p<0.01; **** p<0.0001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
A) Number of total lymphocytes and of CD8+ T cells in the spleen of mice treated with either concomitant or sequential combination of CT and aPD-L1. (B) Representative FACS plots showing the frequency of stem-like (PD-1+TCF-1+TIM-3-), effector transitory (PD-1+CX3CR1+TIM-3+) and terminally differentiated (PD-1+CD101+TIM-3+) Gp33+ CD8 T cells in the spleen across the treatment groups, with quantified numbers shown in (C). Data are pooled from 2 independent experiments of 4-6 mice per group. For statistical analysis the T-test was used, total numbers were Log10 transformed. Bars represent mean and SEM. * p<0.05; ** p<0.01; **** p<0.0001.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A) Number of total lymphocytes, CD8 and CD4 T cells in the spleen across the treatment groups. (B-C) Frequency of PD-1+ and LCMV-specific CD8 T cells in the spleen and in the lung. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis, the one-way ANOVA test was used; total numbers were Log10 transformed. Bars represent mean and SEM. *p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A) Number of total lymphocytes, CD8 and CD4 T cells in the spleen across the treatment groups. (B-C) Frequency of PD-1+ and LCMV-specific CD8 T cells in the spleen and in the lung. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis, the one-way ANOVA test was used; total numbers were Log10 transformed. Bars represent mean and SEM. *p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.